Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity

The bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 has been previously identified as a more potent analog of dexrazoxane (ICRF-187), a drug used in clinical practice against anthracycline cardiotoxicity. However, the poor aqueous solubility of ICRF-193 has precluded its further in vivo deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavlovič Piskáčková, Hana, Jansová, Hana, Kubeš, Jan, Karabanovich, Galina, Váňová, Nela, Kollárová-Brázdová, Petra, Melnikova, Iuliia, Jirkovská, Anna, Lenčová-Popelová, Olga, Chládek, Jaroslav, Roh, Jaroslav, Šimůnek, Tomáš, Štěrba, Martin, Štěrbová-Kovaříková, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904827/
https://www.ncbi.nlm.nih.gov/pubmed/33627707
http://dx.doi.org/10.1038/s41598-021-83688-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904827/
https://www.ncbi.nlm.nih.gov/pubmed/33627707
http://dx.doi.org/10.1038/s41598-021-83688-x

Ejemplares similares